FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileZoetis Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ZTS
Zoetis Inc. Stock AnalysisComprehensive stock analysis for Zoetis Inc. (ZTS) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisZTS
ZTS
Zoetis Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ZTS
  1. Home
  2. Stocks
  3. Zoetis Inc.

Zoetis Inc.

🇺🇸ZTS•NYSE

Zoetis Inc.

🇺🇸ZTS•NYSE
Market cap
$34.29B
Sentiment

Your view on ZTS

Mkt Cap
$34.29B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Zoetis Inc.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Kristin C. Peck
Headquarters
10 Sylvan Way, Parsippany, NJ, US
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Kristin C. Peck
Headquarters
10 Sylvan Way, Parsippany, NJ, US
Description

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms.

It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock.

In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health.

It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Zoetis Inc. from FRC's valuation model, read against the market price. ZTS last traded at $84.39, 14.2× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Zoetis Inc.. Starting points for Zoetis Inc.: P/E 14.2, EPS $6.04, beta 0.68 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Zoetis Inc.. Zoetis Inc. paid $2.12 per share over the last year — a 2.5% yield at the current $84.39 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Zoetis Inc.. Trailing twelve-month EPS for Zoetis Inc. stands at $6.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$97.30

average of 10 firms, last 12 months

 

$97.30

Low $74.00

Median $85.00

High $160.00

 

Analyst Ratings

Hold15 firms, last 12 months
  • Strong Buy0
  • Buy7
  • Hold8
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$1.21$1.49$6.31$6.31
Low estimate$1.13$1.39$6.23$5.92
High estimate$1.32$1.63$6.39$6.60
No. of analysts107910
Year-ago EPS$1.48$1.53$6.02—
Growth-18.3%-2.6%+4.8%—

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$2.18B$2.24B$9.29B$9.29B
Low estimate$2.13B$2.18B$9.23B$9.06B
High estimate$2.24B$2.30B$9.41B$9.65B
No. of analysts961112
Year-ago revenue$2.39B$2.26B$9.47B—
Growth-8.8%-0.8%-1.9%—
Recent analyst actions15 rating and price-target changes, latest Oct 29, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Zoetis Inc.. Zoetis Inc. has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ZTS17 companies · 8 funds
Compare ZTS with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ELANElanco Animal Health IncorporatedDrug Manufacturers - Specialty & Generic$13.2B
  • IDXXIDEXX Laboratories, Inc.Medical - Diagnostics & Research$55.2B
  • MRKMerck & Co., Inc.Drug Manufacturers - General$356.1B
  • NEOGNeogen CorporationMedical - Devices$2.4B
  • PAHCPhibro Animal Health CorporationDrug Manufacturers - Specialty & Generic$1.4B

More Drug Manufacturers - Specialty & Generic companies

  • NPPNYNippon Shinyaku Co., Ltd.OTC$2.3B
  • NSRSNorth Springs Resources CorpOTC$35,902
  • NUGSCannabis Strategic VenturesOTC$187,588
  • NXENNexien BioPharma, Inc.OTC$7,077
  • OGIOrganigram Global Inc.NASDAQ$102M
  • OGI.TOOrganiGram Holdings Inc.TSX$147M
  • OILFFNextleaf Solutions Ltd.OTC$6M
  • OILS.CNNextleaf Solutions Ltd.CNQ$8M
  • OMIDOMID Holdings, Inc.OTC
  • OPTHOptimi Health Corp.NASDAQ$13M
  • OPTI.CNOptimi Health Corp.CNQ$27M
  • ORGOOrganogenesis Holdings Inc.NASDAQ$104M

ETFs holding Zoetis Inc.

% of the fund

  • VOOVanguard S&P 500 ETF$1.0T in assets0.05%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.04%
  • VOVanguard Mid-Cap ETF$103.4B in assets0.28%
  • IVViShares Core SP 500 ETF$852.9B in assets0.05%
  • MOOVanEck Agribusiness ETF$1.1B in assets6.71%
  • IHEiShares US Pharmaceuticals ETF$1.7B in assets4.83%
  • FTXHFirst Trust Nasdaq Pharmaceuticals ETF$1.2B in assets3.69%
  • PPHVanEck Pharmaceutical ETF$1.1B in assets2.69%

Largest holders first, then the funds most concentrated in ZTS.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Zoetis Inc., and how their positions are changing. At a $34.29B market value, institutional positions materially move Zoetis Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Zoetis Inc. executives and directors. Shares of Zoetis Inc. have traded between $117.09 and $181.85 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming Zoetis Inc.. Zoetis Inc. is a $34.29B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Zoetis Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Zoetis Inc.. Coverage tracks Zoetis Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Zoetis Inc.

ZTS Analysis
Good
Past1
Growth4
Health2
Profit5
Value3

News

Latest Market News